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strate improved wound closure rates in these large ulcers
with STSGs, the price difference becomes negligible and
may favor using an STSG.
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Compression Therapy Is Not Necessary After
Endovenous Ablation Therapy for the Treatment of
Varicose Veins
Angela Kokkosis, Harry Schanzer. Surgery, Mount Sinai
Medical Center, New York, NY
Objectives: Compression therapy is routinely used af-
ter endovenous saphenous ablation therapy (EVLT) for the
treatment of varicose veins. The rationale for compression
therapy is enhancement of vein closure and prevention of
superﬁcial thrombophlebitis (STP). A common patient
complaint postoperatively is the discomfort elicited by the
compression. The present work aims to determine whether
compression therapy is necessary as an adjunct to EVLT.
Methods: A total of 77 consecutive lower extremities
in 62 patients were treated with EVLT. Forty-two of the
treated extremities had postoperative compression, and
35 did not. All patients had duplex evaluation at 1 week af-
ter EVLT and then were clinically evaluated at 1 and 3
months. Primary end points were status of the treated
vein, presence or absence of STP, and the degree of vari-
cose vein resolution.
Results: There was no difference between compression
and no-compression groups in sex (63% vs 63% female), age
(59 vs 55 years), CEAP class (C2-C3, 81% vs 91%; C3-C4,
19% vs 9%), extent of varicose veins (<6 mm, 60% vs 66%;
>6 mm, 40% vs 34%), type of vein treated (great saphenous
vein, 80% vs 66%; small saphenous vein, 9% vs 20%; acces-
sory, 11% vs 14%) and operative variables. There was a
95% follow-up rate at 1 week, and all lower extremities
demonstrated saphenous vein closure. Three patients in
the compression group and no patients in the no-compres-
sion group had STP. No patients had deep venous throm-
bosis. At 1 month, both groups had the same rate of
varicose vein regression and need for secondary procedures.
Conclusions: Compression therapy does not add any
further beneﬁt to EVLT and therefore consideration
should be given to eliminating it, thus simplifying and
improving the postoperative recovery.
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Inferior Vena Cava Placement Utilization Among Over
250,000 Patients: National Trends, Complications,
and Relative Contraindications
Sapan S. Desai1, Anahita Dua2. 1Department of Surgery,
Duke University, Houston, Tex; 2Medical College of
Wisconsin, Milwaukee, WiscObjectives: The aim of this study was to evaluate
trends, complications, and risk factors that contribute to
morbidity associated with inferior vena cava (IVC) ﬁlter
placement.
Methods: A retrospective analysis of the National
Inpatient Sample (NIS), a 20% cross-section of all U.S.
inpatient admissions, was completed from 2000 to 2011
by identifying all patients who underwent IVC ﬁlter place-
ment (International Classiﬁcation of Diseases, Ninth Revi-
sion [ICD-9] 38.7). Complications including IVC
thrombosis (ICD-9 45.32) and death were determined.
Variables that were identiﬁed for each patient include
Agency for Healthcare Research and Quality (AHRQ)
standard comorbidities, clinical covariates including age,
gender, race, and insurance status. Propensity matching
was done to evaluate the effect of IVC ﬁlter placement
on reducing morbidity and mortality.
Results: A total of 251,295 patients (52% female)
were identiﬁed using the NIS, of which 2262 (0.9%) devel-
oped thrombosis of the IVC and 17,566 (7%) died. The
average age of admission was 66 years, 14% were elective
admissions. The rate of IVC thrombosis has decreased by
38% since 2000, paralleling the 50% decrease in mortality
over the same time period. Patients with comorbidities
including diabetes, hypertension, obesity, paralysis, chronic
obstructive pulmonary disease, renal failure, and heart dis-
ease were up to 2.3-times less likely to develop IVC throm-
bosis or die after receiving an IVC ﬁlter. Healthy men aged
<66 years were 2.2 times more likely to develop IVC
thrombosis after IVC ﬁlter placement. Overall, IVC ﬁlter
placement decreased morbidity from refractory deep vein
thrombosis and trauma by 30%.
Conclusions: IVC ﬁlter placement is effective in
reducing morbidity and mortality from deep vein throm-
bosis and trauma, particularly among patients aged >65
who have signiﬁcant comorbidities. However, IVC ﬁlter
placement among young, healthy men is disproportionately
associated with complications and its use should be re-eval-
uated among this population.
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Open Surgical vs Endovenous Ablation Treatment of
Patients with Klippel-Trenaunay Syndrome
Jennifer Fahrni, Peter Gloviczki, Manju Kalra, Mark D.
Fleming, Audra A. Duncan, Gustavo S. Oderich,
Haraldur Bjarnason, David Driscoll. Mayo Clinic,
Rochester, Minn
Objectives: To assess safety and efﬁcacy of open surgi-
cal treatment (OST) vs endovenous radiofrequency abla-
tion (RFA) in patients with Klippel-Trenaunay syndrome
(KTS).
Methods: Clinical data of all patients with complex
mixed venous malformation treated for chronic venous
insufﬁciency from 2008 to 2013 were reviewed. Perioper-
ative complications and outcome after OST and RFA
were compared.
Results: Twenty-seven limbs of 26 patients (14 fe-
males; mean age, 33 years; range, 15-74) were treated.
All had varicose veins, 59% had limb overgrowth, and
63% had capillary malformations. Three had previous
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(PE). Inferior vena cava (IVC) ﬁlter was placed in eight.
In group 1, 17 limbs were treated with OST (ligation
and stripping/excision of saphenous or lateral embryonic
veins); in group 2, 10 limbs were treated with RFA. Phle-
bectomies were performed in both groups, with thigh
tourniquet in 21 limbs. Technical success of saphenous/
lateral vein ablation was 100% in group 1 and 90% in
group 2. There was no DVT or PE; none had thrombus
extension into deep veins after RFA. Perioperative compli-
cations occurred in 19% (three of 16) in group 1
(bleeding, wound dehiscence, paresthesia) and in 20%
(two of 10, P ¼ NS) in group 2 (bleeding, thrombophle-
bitis). Follow-up averaged 15 months (range, 1-57
months). No patients reported worsening of symptoms,
and none required repeat interventions. Marked improve-
ment in symptoms was reported in 55% in group 1 and in
25% in group 2 (P ¼ NS). All patients continued to wear
elastic garments.
Conclusions: Surgical and endovenous treatment in
select patients with KTS is safe and can be performed
with low rate of complications. More data are needed
to justify IVC ﬁlter placement. Although symptomatic
varicose veins can be removed, residual symptoms due
to persistent venous insufﬁciency are frequent. Lifelong
elastic support is warranted.
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Operative Explantation of Inferior Vena Cava Filters
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Thomas C. Bower2, Peter Gloviczki2, Samuel R. Money1.
1Vascular and Endovascular, Mayo Clinic, Phoenix, Ariz;
2Mayo Clinic, Rochester, Minn
Objectives: Inferior vena cava (IVC) ﬁlter placement
is not without risk. It has been associated with puncture
site bleeding, venous thrombosis, as well as ﬁlter migra-
tion and perforation. The objective of this study was to
assess our experience with open operative explantation
of IVC ﬁlters.
Methods: After IRB approval, patients were identiﬁed
from case logs that had transabdominal IVC ﬁlter removal
between 1994 and 2013. Patient demographics, thrombo-
embolic risk proﬁle, clinical history, operative indication,
and outcomes were recorded for each case.
Results: Eighteen patients (9 male; mean age, 49.6
years) were identiﬁed. IVC ﬁlters (4 permanent, 8 retriev-
able, 6 unknown) were deployed for a combination of
signiﬁcant thromboembolic events (n ¼ 16), after trauma
(n ¼ 3), or after failure of anticoagulation therapy
(n ¼ 2). Ten patients had retrievable ﬁlters that were
not removed percutaneously due to ﬁlter strut perforation
into surrounding pericaval tissue. Seven patients subse-
quently presented with abdominal/back pain, hematuria,
or sepsis. Midline laparotomy was used for explantation in11 patients during oncologic resections. A subcostal inci-
sion (n ¼ 5) was used for planned explantation alone.
One patient had robotic-assisted laparoscopic removal
and another had an open transjugular removal. Caval
venotomy was primarily closed (n ¼ 15) or patched
with bovine pericardium (n ¼ 2). No complications
attributed to ﬁlter removal were identiﬁed in the postop-
erative period. One patient died of advanced malignancy,
and the other 17 patients remain well (mean follow-up,
618 days).
Conclusions: Filter strut caval perforation remains
the most signiﬁcant indication for transabdominal removal.
Filter removal is often considered incidentally during onco-
logic resection. Although operative explantation still remains
infrequent, our series suggests that it may be performed
safely without signiﬁcant postoperative complications.
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Endovascular Venous Ablation in the Setting of
Warfarin Anticoagulation: Experience at a Single-
Center Institution
Victoria Lee1, Jonathan Ekstroem2, Glenn R. Jacobowitz1.
1Surgery, NYU Medical Center, New York, NY; 2Rutgers
University, Newark, NJ
Objectives: To determine the difference in durability
of venous ablation in patients on warfarin anticoagulation
compared with those without alteration in their coagula-
tion pathway.
Methods: Data were collected from a single-center
institution: NYU Medical Center using International
Classiﬁcation of Diseases, Ninth Revision codes for pa-
tients who had undergone radiofrequency or laser venous
ablation between April 2011 and May 2013. Covidian
CF7-7-60 2nd generation VNUS catheters were used
for radiofrequency ablation and EVLT NeverTouch kits
by Angiodynamics for laser ablation. Patients being
concomitantly treated with warfarin were selected for
study. Follow-up with venous duplex ultrasound imaging
was performed at 1 week, 6 months, and then yearly to
check for thrombus extension from the superﬁcial to
the deep venous system and document occlusion status
of the treated veins.
Results: There were 72 patients: 40 male (55.5%) and
32 female (44.5%), with 94 limbs and 97 procedures per-
formed. Average follow-up time was 142.5 days (range,
7-636 days). Fifty-four procedures (55.7%) were radiofre-
quency ablations, and 43 (44.3%) were laser ablations.
Four veins (4.1%) recanalized within the follow-up time
period: one was a radiofrequency ablation (1.9%), and
three were laser (7.0%). Two of these occurred #1 week,
and the other two between 6 and 12 months after the pro-
cedure. Nine patients (12.5%) in our study were on aspirin
and one (1.3%) was on Plavix, all of whom had successful
venous ablations without recanalization within the
follow-up time period. None of the patients in our study
experienced complications.
